Amgen has already reported the positive topline result of its FOURIER cardiovascular outcomes trial for its PCSK9 inhibitor Repatha, but analysts from Datamonitor Healthcare and Biomedtracker lay out the reasons to check out the full results and other highlights at the upcoming American College of Cardiology meeting.
read full article ›Promising Approaches to Treating Cancer Stalked by Cost Constraints.
read full article ›Detailed results presented at ACC show a reduction in risk of major adverse cardiovascular events, but perhaps not at the level hoped for by payers.
read full article ›New cardiovascular outcomes trial data from Amgen Inc. (NASDAQ: AMGN) PCSK9 inhibitor Repatha evolocumab disappointed investors, but payers are still evaluating the data and Amgen's proposed outcome-based pricing model, which could alleviate their risk.
read full article ›FOURIER outcomes data presented at the American College of Cardiology annual meeting fell short of expectations, but could increase physician demand for the PCSK9 inhibitor, making it harder for payers to say no.
read full article ›When it comes to drug pricing, one size certainly doesn’t fit all. Biopharma firms need to devise and design appropriate pricing and commercial strategies for payers, a group of customers that don’t all care about the same things and, in some cases, whose needs may be diametrically opposed.
read full article ›Some pharmaceutical companies are charging less for drugs as a new strategy amid intense criticism over pricing, reported SwissInfo.
read full article ›Amgen is seeking additional outcomes-based contracts in rheumatoid arthritis through collaboration with Inovalon/Avalere.
read full article ›While investors, media and even some payers have been touting the pricing of three recently launched drugs as sensible, it is not clear whether the lower-than-expected list prices will actually reduce costs to payers. But they are likely to result in lower co-pays for patients, which could increase access.
read full article ›